THE PEMBREIZH MULTICENTER REAL-LIFE COHORT STUDY: FIRST LINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥50%

Abstract

Pembrolizumab is first programmed death protein 1 (PD-1) inhibitor, approved for the first-line locally advanced ormetastatic non-small cell lung cancer (NSCLC)monotherapy, when tumour express high programmed death-ligand 1 (PD-L1) level (≥50%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Approval of pembrolizumab efficacy and safety is based on a series of clinical trials, in which pembrolizumab significantly prolonged overall survival and progression-free survival rates compared with platinum-based chemotherapy for NSCLC patients with high PD-L1 expression, pembrolizumab also and was related with less adverse events.